Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
Submitted by
admin
on November 1, 2009 - 9:00am
Source:
Yahoo/AP
News Tags:
fidaxomicin
Optimer
Clostridium Difficile
Headline:
Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
Do Not Allow Advertisers to Use My Personal information
